New Finding in KRAS Mutated Structure Detected in Colorectal Cancer CRC Tumors Causing Uncontrolled Cell Proliferation in Iraqi Patients

  • Authors

    • Rehab Subhi Ramadhan
    • Rebah Najah Jabbar AL-Gafari
    2018-12-13
    https://doi.org/10.14419/ijet.v7i4.37.23603
  • KRAS, Oncogene, colorectal cancer, pathogenetic mutation.

  • A total 200 tumor samples were collected from patients suffering from colorectal CRC at Al-Amal hospital. Their ages ranged from 40 – 70 years old and distributed according to gender as 130 male and 70 female. We found that CRC was more common in male than female, and more frequent in elderly persons especially in age group of 61 – 70 years old. From 12 specifically designed primers that were able to amplify KRAS gene in those patients’ blood samples, only 2 gave a specific band when tumor sample was used. Molecular analysis of the sequence obtained from those two primers showed the presence of 83 missense mutations in both of them, 20 in the first sequence were associated with pathogenic effect on KRAS gene, 3 frame shift, and 3 insertions, while in the second sequence obtained from primer PK2 4 frame shift mutations, and 4 insertions were identified. The impact finding is that in both sequences, open reading frames (ORFs) were developed that affected cell proliferation dramatically and produced truncated functionless proteins causing KRAS to cease control over cell cycle.

     

     

  • References

    1. [1] Ahmed Gado, Basel Ebeid, Aida Abdelmohsen, Anthony Axon, 2014. Colorectal cancer in Egypt is commoner in young people: Is this cause for alarm? Alexandria Journal of Medicine. 50: 197–201

      [2] References

      [3] Ahmed Gado, Basel Ebeid, Aida Abdelmohsen, Anthony Axon, 2014. Colorectal cancer in Egypt is commoner in young people: Is this cause for alarm? Alexandria Journal of Medicine. 50: 197–201

      [4] Almoguera, C.; Shibata, D.; Forrester, K.; Martin, J.; Arnheim, N.; Perucho, M. 1988. Most human carcinomas of the exocrine pancreas contain mutant C-K-Ras genes. Cell, 53: 549–554.

      [5] Amanda K. Arrington, Eileen L. Heinrich, Wendy Lee, Marjun Duldulao, Supriya Patel, Julian Sanchez, Julio Garcia-Aguilar and Joseph Kim 2012. Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer. Int J Mol Sci. 2012; 13(10): 12153–12168. doi: 10.3390/ijms131012153.

      [6] Baines, A.T.; Xu, D.; Der, C.J. 2011. Inhibition of Ras for cancer treatment: The search continues. Future Med. Chem., 3: 1787–1808.

      [7] Bressler B, Paszat LF, Chen Z, Rothwell DM, Vinden C, Rabeneck L. 2007. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. Gastroenterology; 132:96–102.

      [8] Castagnola P, Giaretti W. 2005. Mutant KRAS, chromosomal instability and prognosis in colorectal cancer. Biochim Biophys Acta.; 1756:115-125.

      [9] Chao A, Thun MJ, Connell CJ, McCullough ML, Jacobs EJ, Flanders WD, et al. 2005. Meat consumption and risk of colorectal cancer. JAMA; 293:172–82.

      [10] Colorectal Cancer. Int. J. Mol. Sci., 13, 12153-12168; doi:10.3390/ijms131012153

      [11] De Roock, W.; Piessevaux, H.; de Schutter, J.; Janssens, M.; de Hertogh, G.; Personeni, N.; Biesmans, B.; van Laethem, J.L.; Peeters, M.; Humblet, Y.; et al. 2008. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol., 19: 508–515.

      [12] Downward J. 2003.Targeting RAS signalling pathways in cancer therapy. Nat Rev.; 3:11-22.

      [13] Ferrari P, Jenab M, Norat T, Moskal A, Slimani N, Olsen A, et al. 2007.Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer.; 121:2065–72.

      [14] H Brenner, M Hoffmeister, V Arndt and U Haug, 2007. Gender differences in colorectal cancer: implications for age at initiation of screening. British Journal of Cancer. 96, 828 – 831

      [15] Haigis KM, Kendall KR, Wang Y, et al. 2008. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet.; 40:600-608.

      [16] Kranenburg, O. 2005. The KRAS oncogene: Past, present, and future. Biochim. Biophys. Acta, 1756: 81–82.

      [17] Lieberman D. 2005. Race, gender, and colorectal cancer screening. Am J Gastroenterol; 100:2756–8.

      [18] Lieberman DA, Holub J, Eisen G, Kraemer D. 2005. Morris CD Utilization of colonoscopy in the United States: results from a national consortium. Gastro intest Endosc 62: 875 –883

      [19] Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev. 2003; 3:7-13.

      [20] Nguyen SP, Bent S, Chen YH, Terdiman JP. 2009. Gender as a risk factor for advanced neoplasia and colorectal cancer: a systematic review and meta-analysis. Clin Gastroenterol Hepatol.; 7:676–81.

      [21] Norat T, Bingham S, Ferrari P, Slimani N, Jenab M, Mazuir M, et al. 2005. Meat, fish, and colorectal cancer risk: the European Prospective Investigation into cancer and nutrition. J Nat. Cancer Inst.; 97:906–16.

      [22] Park JY, Mitrou PN, Dahm CC, Luben RN, Wareham NJ, Khaw KT, et al. Baseline alcohol consumption, type of alcoholic beverage and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition-Norfolk study. Cancer Epidemiol. 2009; 33:347–54.

      [23] Phipps A I; Buchanan, D D; Makar K W; Win A K; Baron J A; Lindor N M; Potter J D; and Newcomb P A .2013. KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Genetics and Genomics. British Journal of Cancer .108:1757–1764. doi:10.1038/bjc.2013.118.

      [24] Rehab Subhi Ramadhan, Aola Sabah Ali and Rebah Najah Algafari 2018. Molecular Analysis of KRAS Mutation Associated with Colorectal Cancer in Iraqi Patients. American Journal of Biochemistry and Biotechnology. 14 (1): 48.56. DOI: 10.3844/ ajbbsp.2018.48.56.

      [25] Roy HK, Bianchi LK. 2009. Differences in colon adenomas and carcinomas among women and men: potential clinical implications. JAMA; 302:1696–7.

      [26] Russo A, Bazan V, Agnese V, et al. 2005. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol.; 16(suppl 4):iv44-iv49.

      [27] Suehiro Y, Wong CW, Chirieac LR, et al. 2008. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res.; 14:2560-2569.

      [28] Thygesen LC, Wu K, Gronbaek M, Fuchs CS, Willett WC, Giovannucci E. Alcohol intake and colorectal cancer: a comparison of approaches for including repeated measures of alcohol consumption. Epidemiology. 2008; 19:258–64.

      [29] Wei EK, Giovannucci E, Wu K, Rosner B, Fuchs CS, Willett WC, et al. Comparison of risk factors for colon and rectal cancer. Int J Cancer. 2004; 108:433–42.

  • Downloads

  • How to Cite

    Subhi Ramadhan, R., & Najah Jabbar AL-Gafari, R. (2018). New Finding in KRAS Mutated Structure Detected in Colorectal Cancer CRC Tumors Causing Uncontrolled Cell Proliferation in Iraqi Patients. International Journal of Engineering & Technology, 7(4.37), 1-11. https://doi.org/10.14419/ijet.v7i4.37.23603